In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a priority review voucher, the US and UK agree to eliminate tariffs on pharmaceutical products, and CMS publishes major price cuts for 15 high-cost Medicare drugs under the latest IRA negotiation round.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a priority review voucher, the US and UK agree to eliminate tariffs on pharmaceutical products, and CMS publishes major price cuts for 15 high-cost Medicare drugs under the latest IRA negotiation round.
Novo Nordisk has submitted a supplemental application to the FDA seeking approval for a higher-dose formulation of Wegovy with a priority review voucher. The company states that the new dose could potentially enhance therapeutic benefit for certain patients as demand for obesity care continues to climb.
In global trade developments, the United States and United Kingdom have reached an agreement to implement zero tariffs on pharmaceutical products, including finished drugs and certain inputs. Officials say the move is designed to strengthen supply-chain resilience, reduce trade friction, and accelerate cross-border access to innovative therapies.
Meanwhile, CMS has released its latest round of Inflation Reduction Act drug price negotiations, announcing significant price cuts for 15 high-cost Medicare therapies. The reductions, which affect drugs commonly used in oncology, cardiometabolic care, and immunology, are expected to lower out-of-pocket costs for millions of beneficiaries.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
